XBIT | XBiotech Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.27 - 6.69
52 Week Range	3.51 - 9.96
Beta	0.77
Implied Volatility	142.90%
IV Rank	48.52%
Day's Volume	46,372
Average Volume	127,819
Shares Outstanding	30,463,200
Market Cap	198,620,064
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-04-15

Valuation
Profitability
Growth
Health
P/E Ratio	-5.62
Forward P/E Ratio	N/A
EPS	-1.16
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	92
Country	USA
Website	XBIT

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

XBIT's peers: GBIO, KRON, ERAS, CCCC, EWTX, PASG, ABSI, ADVM, KZR, ONCT, DAWN, ABOS, XFOR, INZY, VECT, GRTX, ELDN, ICVX, STOK, TSVT, PHAT, REPL

*Chart delayed

Analyzing fundamentals for XBIT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is strong. For more detailed analysis please see XBIT Fundamentals page.

Watching at XBIT technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on XBIT Technicals page.